文献速递肝病消化道肿瘤与早癌

核苷(酸)类似物对慢性乙型肝炎患者主要临床结局的影响:一项为期10年的法国全国队列研究

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10-Year French Nationwide Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-12-31

该研究利用法国国家健康保险数据库,比较慢性乙型肝炎病毒感染者与一般人群的临床负担,并比较替诺福韦与恩替卡韦对肝细胞癌、肝移植和死亡风险的影响。2012至2021年超额死亡率、肝细胞癌发病率和肝移植年均分别下降3.7%、8.0%和11.9%(趋势P<0.001)。在14,054例初治患者中,替诺福韦与恩替卡韦在死亡、肝移植或肝细胞癌复合结局上无差异(HR 1.09;95%CI 0.95-1.24),但替诺福韦与恩替卡韦相比肝细胞癌风险升高(HR 1.31;95%CI 1.07-1.62)。

要点

  • 2012至2021年慢性乙肝患者超额死亡率、肝细胞癌发病率和肝移植年均分别下降3.7%、8.0%和11.9%(趋势P<0.001)。
  • 初治患者中替诺福韦与恩替卡韦在死亡、肝移植或肝细胞癌复合结局上无差异(HR 1.09;95%CI 0.95-1.24)。
  • 替诺福韦与恩替卡韦相比肝细胞癌风险升高(HR 1.31;95%CI 1.07-1.62)。

核心结论

  • 替诺福韦与恩替卡韦相比肝细胞癌风险升高,但两种治疗在死亡或肝脏相关事件的复合结局上无差异。

研究设计与样本

  • 利用法国国家健康保险数据库(SNDS)识别乙肝病毒感染者,将感染者队列与一般人群队列按出生日期、性别、社会剥夺指数和随访开始日期进行1:1精确匹配,量化2012至2021年超额临床负担。
  • 采用逆概率加权比较替诺福韦与恩替卡韦治疗患者的死亡、肝细胞癌和肝移植风险;共101,740例患者与一般人群匹配。
  • 在14,054例初治患者中比较替诺福韦(n=7426)与恩替卡韦(n=6628)的结局。

主要发现

  • 2012至2021年,超额死亡率、肝细胞癌发病率和肝移植的年均下降分别为3.7%、8.0%和11.9%(趋势P<0.001)。
  • 同期核苷(酸)类似物治疗覆盖率显著增加,尤其在2016年之后(P<0.001)。
  • 初治患者中替诺福韦与恩替卡韦在死亡、肝移植或肝细胞癌复合结局上无差异(HR 1.09;95%CI 0.95-1.24)。
  • 替诺福韦与恩替卡韦相比肝细胞癌风险升高(HR 1.31;95%CI 1.07-1.62)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes. AIMS: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality. METHODS: We used the French National Health Insurance Databases (SNDS) to identify HBV-infected patients. We quantified the excess clinical burden from 2012 to 2021 by comparing the HBV-infected cohort with a general population cohort, using 1:1 exact matching on birth date, sex, social deprivation index and follow-up start date. The risks of mortality, HCC and LT were compared between patients treated with tenofovir and entecavir using inverse probability weighting. RESULTS: A total of 101,740 patients were matched to the general population. From 2012 to 2021, the average annual decreases in excess mortality, incidence of HCC and LT were 3.7%, 8.0% and 11.9%, respectively (p for trend < 0.001). During the same period, the nucleos(t)ide analog (NUC) treatment coverage significantly increased, particularly after 2016 (p < 0.001). Among 14,054 treatment-naïve patients starting tenofovir (n = 7426) or entecavir (n = 6628), we observed no difference in the composite outcome of mortality, LT or HCC (HR, 1.09; 95% CI, 0.95-1.24). Tenofovir was associated with an increased risk of HCC compared with entecavir (HR, 1.31; 95% CI, 1.07-1.62). CONCLUSIONS: Tenofovir was associated with a higher risk of HCC compared with entecavir, although no difference in the composite outcome of mortality or liver-related events was observed between the two treatments.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lam L, Bourlière M, Pol S, et al. Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10-Year French Nationwide Cohort Study. Aliment Pharmacol Ther. 2024. PMID: 39737762. doi:10.1111/apt.18462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。